Satoru Iwasa

Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer

Kohei Shitara, Yung‐Jue Bang, Satoru Iwasa et al. · New England Journal of Medicine · 2020 · 1.3K citations · Full text

Medicine, Oncology, Pharmacology +17

Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial

Toshihiro Kudo, Yasuo Hamamoto, Ken Kato et al. · The Lancet Oncology · 2017 · 381 citations

Medicine, Oncology, Pharmacotherapy +7

Feasibility and utility of a panel testing for 114 cancer‐associated genes in a clinical setting: A hospital‐based study

Kuniko Sunami, Hitoshi Ichikawa, Takashi Kubo et al. · Cancer Science · 2019 · 377 citations · Full text

Medicine, Molecular Genetics, Oncology +17

Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Hironobu Hashimoto, Masakazu Abé, Osamu Tokuyama et al. · The Lancet Oncology · 2019 · 235 citations

Medicine, Pharmacology, Pharmacotherapy +16

Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study

Kohei Shitara, Hiroji Iwata, Shunji Takahashi et al. · The Lancet Oncology · 2019 · 229 citations

Medicine, Oncology, Pharmacology +13